What is Prokarium?
Prokarium operates at the intersection of synthetic biology and oncology, specializing in the development of microbial immunotherapies. The company utilizes a proprietary, programmable bacterial strain to deliver targeted treatments, with a primary focus on addressing bladder cancer and other high-unmet-need malignancies. By engineering bacteria to act as therapeutic delivery vehicles, Prokarium's Living Cures platform enhances the efficacy of existing immunotherapies, offering a novel approach to tumor microenvironment modulation. This technological differentiation allows the company to target complex disease pathways that traditional small-molecule drugs often struggle to penetrate, effectively bridging the gap between laboratory discovery and clinical application.
How much funding has Prokarium raised?
Prokarium has raised a total of $66.7M across 4 funding rounds:
Series A
$10M
Other Financing Round
$5.7M
Series B
$21M
Other Financing Round
$30M
Series A (2018): $10M, investors not publicly disclosed
Other Financing Round (2019): $5.7M led by Wellcome Trust
Series B (2020): $21M supported by Riyadh Valley Company, Korea Investment Partners, Flerie Invest, and Future Fund
Other Financing Round (2023): $30M, investors not publicly disclosed
Key Investors in Prokarium
Riyadh Valley Company
The investment arm of King Saud University, Riyadh Valley Company focuses on fostering innovation by providing capital and strategic guidance to high-potential ventures, bridging the gap between academic research and commercial success.
Wellcome Trust
An independent global charitable foundation based in London, Wellcome Trust supports discovery research and tackles urgent health challenges through strategic grants, partnerships, and advocacy to improve global health outcomes.
Future Fund
Established to manage Australia's sovereign wealth, the Future Fund invests for the benefit of future generations, focusing on long-term financial sustainability and supporting public sector fiscal health.
What's next for Prokarium?
With the infusion of this latest capital, Prokarium is well-positioned to accelerate its clinical development pipeline and scale its manufacturing capabilities. The strategic focus will likely shift toward advancing its lead bladder cancer program through critical trial phases while simultaneously expanding the versatility of the Living Cures platform. As the company matures, it will likely seek to strengthen its intellectual property portfolio and explore potential partnerships with larger pharmaceutical entities to facilitate global commercialization. The current funding environment suggests that Prokarium is preparing for a pivotal period of operational expansion, aiming to solidify its leadership in the microbial immunotherapy landscape and deliver transformative outcomes for patients worldwide.
See full Prokarium company page
